Recently the Australian Federal Government announced in the budget significant funding towards mental health initiatives, including $288.9m to approve and MBS item for the highly effective antidepressant treatment repetitive Transcranial Magnetic Stimulation (rTMS).
Dr Sanil Rege, Consultant Psychiatrist and Founder of Psychscene and Psychscenehub speaks to Dr. Martijn Arns, Chief Scientific Adviser, neuroCare Group; Founding Director & Senior Researcher at Research Institute Brainclinics.
New study shows that magnetic brain stimulation (TMS) combined with concurrent psychotherapy is more effective than either technique alone with 66% of research subjects with Depression responding well in an average of 21 session. 65% of the group achieved long-term benefit.
A study by neuroCare's researchers in The Netherlands has looked at the effects of TMS on patients with treatment resistant OCD, finding that 55% of patients responded to treatment and were more likely to respond if they had also addressed a sleep issue.
We integrate leading research, digital therapeutics, physical devices, clinics, and professional education to offer the most comprehensive mental health solutions to patients, therapists and the research community.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.